Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Catechin High Contain Greentea Extract on Improvement of Cognitive Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03826017
Recruitment Status : Recruiting
First Posted : February 1, 2019
Last Update Posted : February 4, 2019
Sponsor:
Information provided by (Responsible Party):
Young Chul Chung, Chonbuk National University Hospital

Brief Summary:
This study was the efficacy and safety of Catechin high contain greentea extract on improvement of Cognitive Function

Condition or disease Intervention/treatment Phase
Cognitive Function Dietary Supplement: Catechin high contain greentea extract Dietary Supplement: Placebo Not Applicable

Detailed Description:
This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate. 80 subjects were participated in Catechin high contain greentea extract or placebo group. To evaluate the changes of the evaluation items when Catechin high contain greentea extract was taken 12 weeks compared with placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A 12 Weeks, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Catechin High Contain Greentea Extract on Improvement of Cognitive Function
Estimated Study Start Date : February 1, 2019
Estimated Primary Completion Date : April 30, 2019
Estimated Study Completion Date : February 28, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Cianidanol

Arm Intervention/treatment
Experimental: Catechin high contain greentea extract
Catechin high contain greentea extract for 260 mg/day 12 weeks.
Dietary Supplement: Catechin high contain greentea extract
Catechin high contain greentea extract 260 mg/day for 12 weeks.

Placebo Comparator: Placebo
Placebo for 12 weeks.
Dietary Supplement: Placebo
Placebo for 12 weeks.




Primary Outcome Measures :
  1. Changes of Visual learning test [ Time Frame: 12 weeks ]
    Visual learning test was measured in baseline and 12 week.

  2. Changes of Korean Version of the Montreal Cognitive Assessment(MoCA-K) [ Time Frame: 12 weeks ]

    Korean Version of the Montreal Cognitive Assessment(MoCA-K) was measured in baseline and 12 week. The cognitive function evaluation using the Montreal Cognitive Assessment(MoCA-K) is a total of 8 items, and evaluates cognitive functions such as time / execution power, vocabulary, memory, attention, sentence, abstraction, delayed recall, and orientation.

    Time / execution power's total score is 5 points, vocabulary's total score is 3 points, attention's total score is 3 points, sentence's total score is 3 points, abstraction's total score is 2 points, delayed recall's total score is 5 points, orientation's total score is 6 points. It takes about 10 minutes to complete, and the total score is 30 points and total score make sum score. A score of 23 points or more is regarded as normal. If you have less than 6 years of education, add 1 point.



Secondary Outcome Measures :
  1. Changes of Auditory continuous performance test [ Time Frame: 12 weeks ]
    Auditory continuous performance test was measured in baseline and 12 week.

  2. Changes of Verbal learning test [ Time Frame: 12 weeks ]
    Verbal learning test was measured in baseline and 12 week.

  3. Changes of Visual working memory test [ Time Frame: 12 weeks ]
    Visual working memory test was measured in baseline and 12 week.

  4. Changes of Perceived stress scale(PSS) [ Time Frame: 12 weeks ]
    Perceived stress scale(PSS) was measured in baseline and 12 week. It consists of 10 questions. Each question is evaluated from 0 (none) to 4 (very often), and 4 items (4, 5, 7, 8) are scored back and added to the remaining questions. The duration of the last month should be presented before implementation (if the duration is longer, the predictability is lowered).

  5. Changes of Beck Depression Inventory(BDI) [ Time Frame: 12 weeks ]
    Beck Depression Inventory(BDI) was measured in baseline and 12 week. It consists of 21 items including cognitive, emotional, synchronous, and physical symptoms of depression. The total score ranges from 0~63 points for each question. Beck Depression Inventory(BDI) score is 0 ~ 9 points non-depression, 10 ~ 15 is mild depression, 16 ~ 23 is moderate depression, and 24 ~ 63 is severe depression.

  6. Changes of Brain-derived neurotrophic factor(BDNF) [ Time Frame: 12 weeks ]
    Brain-derived neurotrophic factor(BDNF)(pg/mL) was measured in baseline and 12 week.

  7. Changes of Total antioxidant status(TAS) [ Time Frame: 12 weeks ]
    Total antioxidant status(TAS) was measured in baseline and 12 week.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Those who are at least 60 years of age at screening
  • Those who have Korean Mini-Mental Status Examination(K-MMSE) result 25-28 points
  • Those who agree to voluntary participation and to comply with the Notice after fully hearing and understanding the details of this human trial

Exclusion Criteria:

  • Those with a past history of treatment with Axis I disorder in SCID(Structured Clinical Interview for DSM-IV) which is a structured clinical interview in the Diagnostic and Statistical Manual of Mental Disorders at Screening or who have been treated within the last 3 years
  • Those with alcohol abuse or dependence within the last 3 months
  • Those who have clinically significant following severe illness (Epilepsy, mental retardation, brain nervous system diseases, endocrine diseases, blood / malignant tumors, cardiovascular diseases, Crohn's disease, etc.)
  • Those with a history of clinically significant hypersensitivity to green tea
  • Those taking medicines, health functional foods or herbal medicines related to improvement of cognitive function and memory within 1 month before screening
  • Those who ingested green tea extract's health functional food within 1 month before screening
  • Those who whole blood donation within 1 months before the first ingestion or Component blood donation within 2 weeks
  • Those who participate in other human tiral within 3 months
  • Those who shows the following results in the Laboratory test

    • AST, ALT > 3 times upper limit of normal range
    • Other significant laboratory test opinion
  • Those who is deemed unsuitable for participating in the human trial due to other reasons

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03826017


Contacts
Layout table for location contacts
Contact: Young-chul Chung, MD 82 63 250 2185 chungyc@jbnu.ac.kr

Locations
Layout table for location information
Korea, Republic of
Department of Psychiatry, Chonbuk National University Hospital Recruiting
Jeonju, Jeollabuk-do, Korea, Republic of, 54907
Contact: Lee Na Kim    82 10 7112 1894      
Sponsors and Collaborators
Chonbuk National University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Young-chul Chung, MD Chonbuk National University Hospital

Layout table for additonal information
Responsible Party: Young Chul Chung, Professor of Psychiatry, Chonbuk National University Hospital
ClinicalTrials.gov Identifier: NCT03826017     History of Changes
Other Study ID Numbers: RNO-CF-EG
First Posted: February 1, 2019    Key Record Dates
Last Update Posted: February 4, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Young Chul Chung, Chonbuk National University Hospital:
Catechin high contain greentea extract
Cognitive Function